Baricitinib and other oral JAK inhibitors show promise as effective treatments for moderate-to-severe alopecia areata (AA), with fewer adverse effects compared with traditional options. Patients with ...
Please provide your email address to receive an email when new articles are posted on . Upadacitinib is an oral JAK inhibitor under investigation for the treatment of multiple dermatologic indications ...
Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is an interleukin-2 receptor pathway agonist that has shown success in other autoimmune ...
A greater proportion of patients treated with deuruxolitinib 8mg achieved a SALT score of less than or equal to 20 (80% or more scalp hair) compared with placebo. The Food and Drug Administration (FDA ...
Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...
TUESDAY, March 18, 2025 (HealthDay News) -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for ...
Researchers examined the impact of baricitinib withdrawal and retreatment on hair regrowth in patients with severe alopecia areata. Although baricitinib has demonstrated efficacy for treating patients ...
The FDA has granted a “Fast Track” designation to rezpegaldesleukin (REZPEG) as a treatment for severe-to-very severe alopecia areata, according to a press release from the manufacturer, Nektar ...
For many people, alopecia areata presents as small, well-defined patches of hair loss on the scalp. But for others with severe cases, the unpredictable autoimmune disease can progress to a complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback